LPI (LP Information)' newest research report, the “Ankylosing Spondylitis Drug Industry Forecast” looks at past sales and reviews total world Ankylosing Spondylitis Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Ankylosing Spondylitis Drug sales for 2023 through 2029. With Ankylosing Spondylitis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ankylosing Spondylitis Drug industry.
This Insight Report provides a comprehensive analysis of the global Ankylosing Spondylitis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ankylosing Spondylitis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ankylosing Spondylitis Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ankylosing Spondylitis Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ankylosing Spondylitis Drug.
The global Ankylosing Spondylitis Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Ankylosing Spondylitis Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Ankylosing Spondylitis Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Ankylosing Spondylitis Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Ankylosing Spondylitis Drug players cover Amgen, Wyeth, Takeda, Centocor, Schering-Plough, Mitsubishi Tanabe, Abbott, Eisai and Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Ankylosing Spondylitis Drug market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Cimzia
Enbrel
Humira
Remicade
Simponi
Others
Segmentation by application
Hospitals
Clinics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amgen
Wyeth
Takeda
Centocor
Schering-Plough
Mitsubishi Tanabe
Abbott
Eisai
Pfizer
Johnson & Johnson

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Ankylosing Spondylitis Drug Market Size 2018-2029 2.1.2 Ankylosing Spondylitis Drug Market Size CAGR by Region 2018 VS 2022 VS 2029 2.2 Ankylosing Spondylitis Drug Segment by Type 2.2.1 Cimzia 2.2.2 Enbrel 2.2.3 Humira 2.2.4 Remicade 2.2.5 Simponi 2.2.6 Others 2.3 Ankylosing Spondylitis Drug Market Size by Type 2.3.1 Ankylosing Spondylitis Drug Market Size CAGR by Type (2018 VS 2022 VS 2029) 2.3.2 Global Ankylosing Spondylitis Drug Market Size Market Share by Type (2018-2023) 2.4 Ankylosing Spondylitis Drug Segment by Application 2.4.1 Hospitals 2.4.2 Clinics 2.5 Ankylosing Spondylitis Drug Market Size by Application 2.5.1 Ankylosing Spondylitis Drug Market Size CAGR by Application (2018 VS 2022 VS 2029) 2.5.2 Global Ankylosing Spondylitis Drug Market Size Market Share by Application (2018-2023) 3 Ankylosing Spondylitis Drug Market Size by Player 3.1 Ankylosing Spondylitis Drug Market Size Market Share by Players 3.1.1 Global Ankylosing Spondylitis Drug Revenue by Players (2018-2023) 3.1.2 Global Ankylosing Spondylitis Drug Revenue Market Share by Players (2018-2023) 3.2 Global Ankylosing Spondylitis Drug Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Ankylosing Spondylitis Drug by Regions 4.1 Ankylosing Spondylitis Drug Market Size by Regions (2018-2023) 4.2 Americas Ankylosing Spondylitis Drug Market Size Growth (2018-2023) 4.3 APAC Ankylosing Spondylitis Drug Market Size Growth (2018-2023) 4.4 Europe Ankylosing Spondylitis Drug Market Size Growth (2018-2023) 4.5 Middle East & Africa Ankylosing Spondylitis Drug Market Size Growth (2018-2023) 5 Americas 5.1 Americas Ankylosing Spondylitis Drug Market Size by Country (2018-2023) 5.2 Americas Ankylosing Spondylitis Drug Market Size by Type (2018-2023) 5.3 Americas Ankylosing Spondylitis Drug Market Size by Application (2018-2023) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Ankylosing Spondylitis Drug Market Size by Region (2018-2023) 6.2 APAC Ankylosing Spondylitis Drug Market Size by Type (2018-2023) 6.3 APAC Ankylosing Spondylitis Drug Market Size by Application (2018-2023) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Ankylosing Spondylitis Drug by Country (2018-2023) 7.2 Europe Ankylosing Spondylitis Drug Market Size by Type (2018-2023) 7.3 Europe Ankylosing Spondylitis Drug Market Size by Application (2018-2023) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Ankylosing Spondylitis Drug by Region (2018-2023) 8.2 Middle East & Africa Ankylosing Spondylitis Drug Market Size by Type (2018-2023) 8.3 Middle East & Africa Ankylosing Spondylitis Drug Market Size by Application (2018-2023) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Ankylosing Spondylitis Drug Market Forecast 10.1 Global Ankylosing Spondylitis Drug Forecast by Regions (2024-2029) 10.1.1 Global Ankylosing Spondylitis Drug Forecast by Regions (2024-2029) 10.1.2 Americas Ankylosing Spondylitis Drug Forecast 10.1.3 APAC Ankylosing Spondylitis Drug Forecast 10.1.4 Europe Ankylosing Spondylitis Drug Forecast 10.1.5 Middle East & Africa Ankylosing Spondylitis Drug Forecast 10.2 Americas Ankylosing Spondylitis Drug Forecast by Country (2024-2029) 10.2.1 United States Ankylosing Spondylitis Drug Market Forecast 10.2.2 Canada Ankylosing Spondylitis Drug Market Forecast 10.2.3 Mexico Ankylosing Spondylitis Drug Market Forecast 10.2.4 Brazil Ankylosing Spondylitis Drug Market Forecast 10.3 APAC Ankylosing Spondylitis Drug Forecast by Region (2024-2029) 10.3.1 China Ankylosing Spondylitis Drug Market Forecast 10.3.2 Japan Ankylosing Spondylitis Drug Market Forecast 10.3.3 Korea Ankylosing Spondylitis Drug Market Forecast 10.3.4 Southeast Asia Ankylosing Spondylitis Drug Market Forecast 10.3.5 India Ankylosing Spondylitis Drug Market Forecast 10.3.6 Australia Ankylosing Spondylitis Drug Market Forecast 10.4 Europe Ankylosing Spondylitis Drug Forecast by Country (2024-2029) 10.4.1 Germany Ankylosing Spondylitis Drug Market Forecast 10.4.2 France Ankylosing Spondylitis Drug Market Forecast 10.4.3 UK Ankylosing Spondylitis Drug Market Forecast 10.4.4 Italy Ankylosing Spondylitis Drug Market Forecast 10.4.5 Russia Ankylosing Spondylitis Drug Market Forecast 10.5 Middle East & Africa Ankylosing Spondylitis Drug Forecast by Region (2024-2029) 10.5.1 Egypt Ankylosing Spondylitis Drug Market Forecast 10.5.2 South Africa Ankylosing Spondylitis Drug Market Forecast 10.5.3 Israel Ankylosing Spondylitis Drug Market Forecast 10.5.4 Turkey Ankylosing Spondylitis Drug Market Forecast 10.5.5 GCC Countries Ankylosing Spondylitis Drug Market Forecast 10.6 Global Ankylosing Spondylitis Drug Forecast by Type (2024-2029) 10.7 Global Ankylosing Spondylitis Drug Forecast by Application (2024-2029) 11 Key Players Analysis 11.1 Amgen 11.1.1 Amgen Company Information 11.1.2 Amgen Ankylosing Spondylitis Drug Product Offered 11.1.3 Amgen Ankylosing Spondylitis Drug Revenue, Gross Margin and Market Share (2018-2023) 11.1.4 Amgen Main Business Overview 11.1.5 Amgen Latest Developments 11.2 Wyeth 11.2.1 Wyeth Company Information 11.2.2 Wyeth Ankylosing Spondylitis Drug Product Offered 11.2.3 Wyeth Ankylosing Spondylitis Drug Revenue, Gross Margin and Market Share (2018-2023) 11.2.4 Wyeth Main Business Overview 11.2.5 Wyeth Latest Developments 11.3 Takeda 11.3.1 Takeda Company Information 11.3.2 Takeda Ankylosing Spondylitis Drug Product Offered 11.3.3 Takeda Ankylosing Spondylitis Drug Revenue, Gross Margin and Market Share (2018-2023) 11.3.4 Takeda Main Business Overview 11.3.5 Takeda Latest Developments 11.4 Centocor 11.4.1 Centocor Company Information 11.4.2 Centocor Ankylosing Spondylitis Drug Product Offered 11.4.3 Centocor Ankylosing Spondylitis Drug Revenue, Gross Margin and Market Share (2018-2023) 11.4.4 Centocor Main Business Overview 11.4.5 Centocor Latest Developments 11.5 Schering-Plough 11.5.1 Schering-Plough Company Information 11.5.2 Schering-Plough Ankylosing Spondylitis Drug Product Offered 11.5.3 Schering-Plough Ankylosing Spondylitis Drug Revenue, Gross Margin and Market Share (2018-2023) 11.5.4 Schering-Plough Main Business Overview 11.5.5 Schering-Plough Latest Developments 11.6 Mitsubishi Tanabe 11.6.1 Mitsubishi Tanabe Company Information 11.6.2 Mitsubishi Tanabe Ankylosing Spondylitis Drug Product Offered 11.6.3 Mitsubishi Tanabe Ankylosing Spondylitis Drug Revenue, Gross Margin and Market Share (2018-2023) 11.6.4 Mitsubishi Tanabe Main Business Overview 11.6.5 Mitsubishi Tanabe Latest Developments 11.7 Abbott 11.7.1 Abbott Company Information 11.7.2 Abbott Ankylosing Spondylitis Drug Product Offered 11.7.3 Abbott Ankylosing Spondylitis Drug Revenue, Gross Margin and Market Share (2018-2023) 11.7.4 Abbott Main Business Overview 11.7.5 Abbott Latest Developments 11.8 Eisai 11.8.1 Eisai Company Information 11.8.2 Eisai Ankylosing Spondylitis Drug Product Offered 11.8.3 Eisai Ankylosing Spondylitis Drug Revenue, Gross Margin and Market Share (2018-2023) 11.8.4 Eisai Main Business Overview 11.8.5 Eisai Latest Developments 11.9 Pfizer 11.9.1 Pfizer Company Information 11.9.2 Pfizer Ankylosing Spondylitis Drug Product Offered 11.9.3 Pfizer Ankylosing Spondylitis Drug Revenue, Gross Margin and Market Share (2018-2023) 11.9.4 Pfizer Main Business Overview 11.9.5 Pfizer Latest Developments 11.10 Johnson & Johnson 11.10.1 Johnson & Johnson Company Information 11.10.2 Johnson & Johnson Ankylosing Spondylitis Drug Product Offered 11.10.3 Johnson & Johnson Ankylosing Spondylitis Drug Revenue, Gross Margin and Market Share (2018-2023) 11.10.4 Johnson & Johnson Main Business Overview 11.10.5 Johnson & Johnson Latest Developments 12 Research Findings and Conclusion